Search Results
You are looking at 1 - 1 of 1 items for
- Author: Kalliopi Pazaitou-Panayiotou x
Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
Introduction: Tyrosine kinase inhibitors (TKIs) have been used in patients with advanced medullary thyroid carcinoma (MTC); however, data on their effectiveness and safety are limited. The aim of this systematic review and meta-analysis was to document clinical response and toxicities of TKIs in advanced MTC. Methods: We systematically searched major databases for articles or abstracts on TKI use in MTC patients until May 2018. Objective response (OR), defined as the sum of complete + partial response, expressed as percentage, was our primary endpoint, while disease stability, disease progression (DP), median progression-free survival (PFS), and drug discontinuation rate due to adverse events (AEs) were secondary endpoints. Pooled percentages, PFS time, and 95% CIs were reported. Results: Thirty-three publications were finally included in the analysis: 1 phase IV, 2 phase III trials evaluating vandetanib and cabozantinib, respectively, 20 phase I or II studies, and the remaining 10 studies of retrospective-observational nature. OR was documented in 28.6% (95% CI 25.9–31.9) of patients. Stable disease was recorded in 46.2% (95% CI 43.3–49.1). Overall, DP was observed in 22.9% (95% CI 20.4–27.6). Grade 3 or more AEs occurred in 48.5% (95% CI 45.5–51.5) of patients, and drug discontinuation was reported in 44.7% (95% CI 41.7–47.6). In general, use of TKIs conferred a PFS of 23.3 months (95% CI 21.07–25.5). In particular, vandetanib induced an OR in 33.8% (95% CI 29.6–38.0) of patients and cabozantinib in 27.7% (95% CI 22.05–33.4). DP occurred in 23.7% (95% CI 19.9–27.6) with vandetanib use and in 22.6% (95% CI 17.4–27.9) in cabozantinib-treated patients. Sorafenib, the third most frequently studied drug, showed intermediate efficacy, but higher discontinuation rates. Conclusion: Treatment with TKIs in MTC patients with progressive disease is associated with a moderate therapeutic benefit, with achievement of either disease stability or partial response in 73%. The toxicity of these drugs is not negligible, but it is, nonetheless, manageable.